Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma
Molecular Templates Announces Start of Phase 1 Clinical Trial of MT-3724 in Refractory Non-Hodgkin’s Lymphoma
Pu37blished on Thursday, 05 March 2015
Molecular Templates라는 clinical stage biotechnology company 가 MT-3724를 가지고 refractory non-Hodgkin’s lymphoma (NHL) 환자에 대한 임상 1상을 시작한다는 발표.
계속 임상 시험을 위한 환자를 모집중이고, 현재 40명의 환자자 등록된 상태.
임상1상에서는 “dose-escalation study”를 통하여 safety, pharmacokinetics, pharmacodynamics를 평가할 예정. 또한 anti-tumor activity를 측정할 예정.
Molecular Templates is a clinical stage biopharmaceutical company that develops next-generation immunotoxins for the treatment of cancer and other serious diseases. These immunotoxins are derived from a bacterial toxin that has been genetically engineered to reduce its immunogenicity. This new toxin scaffold has been fused to randomized scFv fragments and expressed on phage display to create screenable libraries of next generation immunotoxins called Engineered Toxin Bodies (ETBs). These ETBs retain the parent toxin's ability to force internalization, route through the cell in an anticipatory manner, and enzymatically and irreversibly inhibit ribosome activity but have substantially reduced immunogenicity compared to the parent bacterial toxin. The company's lead compound, MT-3724, is the first immunotoxin to target CD20 and will enter clinical trials for the treatment on refractory non-Hodgkin's lymphoma in the fourth quarter of 2014.
(원본)